Phase 2 Multicenter Single-Arm Study of Second-Line Axitinib in Favorable Risk Patients with Metastatic Renal Cell Carcinoma: FavorAx.
Tsimafeyeu I, Borisov P, Abdelgafur A, Leonenkov R, Novikova O, Guseva I, Demchenkova M, Mikhailova N, Semenov A, Yurmazov Z, Sivunova I, Ramazanova M, Gamayunov S, Kosov D, Bratslavsky G.
Tsimafeyeu I, et al.
Target Oncol. 2019 Feb;14(1):33-38. doi: 10.1007/s11523-018-0613-y.
Target Oncol. 2019.
PMID: 30607698
Clinical Trial.